• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.

作者信息

du Bois Andreas, Baert Thaïs, Vergote Ignace

机构信息

Kliniken Essen-Mitte, Essen, Germany.

Katholieke Universiteit Leuven, Leuven, Belgium.

出版信息

J Clin Oncol. 2019 Sep 20;37(27):2398-2405. doi: 10.1200/JCO.19.00022. Epub 2019 Aug 12.

DOI:10.1200/JCO.19.00022
PMID:31403864
Abstract
摘要

相似文献

1
Role of Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer.新辅助化疗在晚期上皮性卵巢癌中的作用
J Clin Oncol. 2019 Sep 20;37(27):2398-2405. doi: 10.1200/JCO.19.00022. Epub 2019 Aug 12.
2
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).随机试验原发性肿瘤细胞减灭术与新辅助化疗治疗晚期上皮性卵巢癌（SCORPION-NCT01461850）。
Int J Gynecol Cancer. 2020 Nov;30(11):1657-1664. doi: 10.1136/ijgc-2020-001640. Epub 2020 Oct 7.
3
Diagnosis and Treatment of Ovarian Cancer.卵巢癌的诊断与治疗
Hematol Oncol Clin North Am. 2018 Dec;32(6):943-964. doi: 10.1016/j.hoc.2018.07.010.
4
Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.新辅助化疗后间隔细胞减灭术和 HIPEC 治疗原发性晚期 IIIC/IVA 上皮性卵巢癌的复发模式。
Eur J Surg Oncol. 2021 Jun;47(6):1427-1433. doi: 10.1016/j.ejso.2021.01.013. Epub 2021 Jan 22.
5
HIPEC improves survival in stage III epithelial ovarian cancer.腹腔热灌注化疗可提高Ⅲ期上皮性卵巢癌患者的生存率。
Lancet Oncol. 2018 Mar;19(3):e138. doi: 10.1016/S1470-2045(18)30065-2. Epub 2018 Jan 26.
6
Neoadjuvant chemotherapy fails to improve survival in advanced ovarian cancer: but is it the real culprit?新辅助化疗未能提高晚期卵巢癌患者的生存率：但它真的是罪魁祸首吗？
Int J Gynecol Cancer. 2011 May;21(4):596. doi: 10.1097/IGC.0b013e318214d4af.
7
A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.贝伐珠单抗联合新辅助化疗序贯中间型减瘤术治疗卵巢癌的单中心回顾性研究。
Yonsei Med J. 2020 Apr;61(4):284-290. doi: 10.3349/ymj.2020.61.4.284.
8
Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study.贝伐珠单抗联合新辅助化疗和间隔减瘤术治疗晚期上皮性卵巢癌的安全性和有效性：一项可行性研究。
J Surg Oncol. 2018 Sep;118(4):687-693. doi: 10.1002/jso.25187. Epub 2018 Sep 11.
9
Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study.日本上皮性卵巢癌的新辅助化疗：JSGO-JSOG联合研究
J Gynecol Oncol. 2019 Nov;30(6):e113. doi: 10.3802/jgo.2019.30.e113.
10
Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.在接受新辅助化疗的晚期卵巢癌患者中，间隔减瘤术后 CA-125 再次升高的预后意义。
Eur J Surg Oncol. 2019 Apr;45(4):644-649. doi: 10.1016/j.ejso.2018.10.053. Epub 2018 Oct 11.

引用本文的文献

1
CT and MRI in Advanced Ovarian Cancer: Advances in Imaging Techniques.晚期卵巢癌的CT与MRI：成像技术进展
Korean J Radiol. 2025 Sep;26(9):841-854. doi: 10.3348/kjr.2025.0357.
2
Thermoresponsive Hyaluronate-Based Nanogels for Enhanced Phenanthriplatin Delivery in Cisplatin-Resistant Ovarian Cancer.用于增强菲铂在顺铂耐药卵巢癌中递送的基于热响应性透明质酸的纳米凝胶
Biomacromolecules. 2025 Aug 11;26(8):5232-5244. doi: 10.1021/acs.biomac.5c00692. Epub 2025 Jul 22.
3
Characteristics and Outcomes of Children and Adolescents With Epithelial Ovarian Neoplasms From a Tertiary Cancer Centre in Western India: A Retrospective Study.
印度西部一家三级癌症中心上皮性卵巢肿瘤儿童和青少年的特征及结局：一项回顾性研究
Cureus. 2025 May 22;17(5):e84650. doi: 10.7759/cureus.84650. eCollection 2025 May.
4
Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis.贝伐单抗在卵巢癌新辅助化疗中的疗效与安全性分析：一项系统评价与荟萃分析
Front Pharmacol. 2025 May 30;16:1566604. doi: 10.3389/fphar.2025.1566604. eCollection 2025.
5
Niraparib restricts intraperitoneal metastases of ovarian cancer by eliciting CD36-dependent ferroptosis.尼拉帕利通过引发CD36依赖的铁死亡来限制卵巢癌的腹膜转移。
Redox Biol. 2025 Mar;80:103528. doi: 10.1016/j.redox.2025.103528. Epub 2025 Feb 3.
6
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial.中国新辅助化疗联合或不联合替雷利珠单抗随后进行减瘤手术治疗卵巢癌（NAIVE研究）的疗效和安全性：一项开放标签、II期、随机对照试验的研究方案
BMJ Open. 2025 Feb 5;15(2):e092545. doi: 10.1136/bmjopen-2024-092545.
7
Intratumoral and peritumoral MRI-based radiomics for predicting extrapelvic peritoneal metastasis in epithelial ovarian cancer.基于磁共振成像（MRI）的肿瘤内和瘤周影像组学预测上皮性卵巢癌盆腔外腹膜转移
Insights Imaging. 2024 Nov 22;15(1):281. doi: 10.1186/s13244-024-01855-w.
8
Peripheral NK cell count predicts response and prognosis in breast cancer patients underwent neoadjuvant chemotherapy.外周 NK 细胞计数可预测接受新辅助化疗的乳腺癌患者的反应和预后。
Front Immunol. 2024 Sep 30;15:1437193. doi: 10.3389/fimmu.2024.1437193. eCollection 2024.
9
The Influence of Circulating Immune Cell and CA125 Dynamics on Neoadjuvant Therapy Selection for Advanced Ovarian Cancer.循环免疫细胞和 CA125 动态变化对晚期卵巢癌新辅助治疗选择的影响。
Medicina (Kaunas). 2024 Aug 9;60(8):1290. doi: 10.3390/medicina60081290.
10
Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer.单细胞 RNA 测序揭示恶性上皮细胞中的 MYBL2 参与卵巢癌的发生和发展。
Front Immunol. 2024 Jul 29;15:1438198. doi: 10.3389/fimmu.2024.1438198. eCollection 2024.